Ertugliflozin (Steglatro®)

Assessment Status Rapid review complete
Drug Ertugliflozin
Brand Steglatro®
Indication For the treatment of the treatment 2 diabetes mellitus (T2DM) in individuals 18 years and over to improve glycaemic control.
Assessment Process
Rapid review commissioned 13/03/2018
Rapid review completed 21/05/2018
Rapid review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that ertugliflozin be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; July 2018